Uric acid in the early risk stratification of ST-elevation myocardial infarction

被引:0
|
作者
Chiara Lazzeri
Serafina Valente
Marco Chiostri
Claudio Picariello
Gian Franco Gensini
机构
[1] Azienda Ospedaliero-Universitaria Careggi,Intensive Cardiac Care Unit, Heart and Vessel Department
来源
关键词
Uric acid; Risk stratification; ST-elevation myocardial infarction; Percutaneous coronary intervention;
D O I
暂无
中图分类号
学科分类号
摘要
Controversy still exists about uric acid as a potential prognosticrisk factor for outcomes in patients with acute myocardial infarction. We prospectively assessed, in 856 patients with ST-elevation myocardial infarction (STMI) consecutively admitted to our Intensive Cardiac Care Unit after primary percutaneous coronary intervention (PCI) whether uric acid (UA) levels are associated with in-hospital mortality and complications. Killip classes III-–IV were more frequent in the 3° UA tertile that was associated with the highest values of peak Tn I (p = 0.005), NT-proBNP (p < 0.001), and fibrinogen (p = 0.036). Uric acid was associated with mortality (crude OR: 1.24; 95% CI 1.03–1.51; p = 0.025), but, when adjusted for Tn I and renal failure (as inferred by eGFR <60 ml/min/1.73 m2), uric acid lost its statistical significance, while Tn I (100 pg/ml step OR: 1.002; 95% CI 1.000–1.003; p = 0.007) and renal failure (OR 9.16; 95% CI 3.60–23.32; p < 0.001) were independent predictors for in-ICCU mortality. Uric acid remained as independent predictor for in-ICCU complications (1 mg/dl step OR: 1.11; 95% CI 1.01–1.21; p = 0.030) together with admission glycemia (1 g/dl step OR: 1.50; 95% CI 1.19–1.91; p < 0.001) and renal failure (OR: 1.46; 95% CI 0.99–2.16; p < 0.001). In STEMI patients submitted to PCI, increased uric acid levels identify a subgroup more prone to in-ICCU complications, probably because hyperuricemia stems from several complex mechanisms ranging from pre-existing risk factors to the degree of myocardial ischemia (as indicated by Killip class, ejection fraction) and to the acute metabolic response (as inferred by glucose levels). Hyperuricemia is not independently associated with early mortality when adjusted for renal function and the degree of myocardial damage.
引用
收藏
页码:33 / 39
页数:6
相关论文
共 50 条
  • [22] Strategies to improve early reperfusion in ST-elevation myocardial infarction
    Faxon, David P.
    Jacobs, Alice K.
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2007, 8 (03) : 127 - 134
  • [23] Diagnosis of ST-Elevation Myocardial Infarction
    Wadas, Theresa
    JNP-JOURNAL FOR NURSE PRACTITIONERS, 2013, 9 (02): : 124 - 125
  • [24] Biomarkers and ST-elevation myocardial infarction
    Mueller, Christian
    HEART, 2013, 99 (16) : 1143 - 1143
  • [25] The association between serum uric acid level and heart failure and mortality in the early period of ST-elevation acute myocardial infarction
    Gazi, Emine
    Temiz, Ahmet
    Altun, Burak
    Barutcu, Ahmet
    Bekler, Adem
    Gungor, Omer
    Yener, Ali Umit
    Kurt, Tolga
    Ozcan, Sedat
    Gazi, Sabri
    TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, 2014, 42 (06): : 501 - 508
  • [26] Association of serum uric acid level with mortality and morbidity of patients with acute ST-elevation myocardial infarction
    Hajizadeh, Reza
    Ghaffari, Samad
    Salehi, Rezvanieh
    Mazani, Sarvin
    Aghavali, Sharmin
    JOURNAL OF CARDIOVASCULAR AND THORACIC RESEARCH, 2016, 8 (02) : 56 - 60
  • [27] Treatment of ST-elevation myocardial infarction
    Hermanides, Rik
    Ottervanger, Jan Paul
    FUTURE CARDIOLOGY, 2008, 4 (04) : 391 - 397
  • [28] ST-Elevation Myocardial Infarction Track
    Abella, Benjamin S.
    Otterspoor, Luuk
    Nichol, Graham
    Martin, Jack L.
    THERAPEUTIC HYPOTHERMIA AND TEMPERATURE MANAGEMENT, 2021, 11 (02) : 65 - 70
  • [29] Clopidogrel in ST-elevation myocardial infarction
    Sabatine, Marc S.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2006, 8 (0G) : G31 - G34
  • [30] Ticagrelor in ST-Elevation Myocardial Infarction
    Sgueglia, Gregory A.
    Tarantini, Giuseppe
    Niccoli, Giampaolo
    CURRENT VASCULAR PHARMACOLOGY, 2012, 10 (04) : 458 - 462